Highlights Johnson & Johnson Swiss Exchange

Equities

JNJ

US4781601046

Real-time Estimate Cboe BZX Other stock markets 15:16:54 21/06/2024 BST			5-day change	1st Jan Change
148.4 ^USD	+9.14%		-0.73%	0.00%

02:39pm	Johnson & Johnson: filing in Crohn's disease	CF
02:19pm	Johnson & Johnson: acquisition of Proteologix completed	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson: acquisition of Proteologix completed	01:19pm	CF
Johnson & Johnson Completes Acquisition of Proteologix	01:17pm	MT
Johnson & Johnson Completes Acquisition of Proteologix	12:37pm	MT
Johnson & Johnson Completes Acquisition of Proteologix	12:36pm	MT
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	06-20	MT
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	06-20	CI
J&J: launches open, secure digital ecosystem	06-20	CF
J&J: promising results in Crohn's disease	06-20	CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	06-20	MT
Johnson & Johnson Sees Positive Trial Results for Tremfya	06-20	DJ
Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease	06-20	CI
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	06-17	CI
J&J: positive results in Sjögren's disease	06-17	CF
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints	06-17	MT
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study	06-15	CI
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE
J&J: encouraging trial in relapsing multiple myeloma	06-14	CF
J&J: the promise of ibrutinib in CLL	06-14	CF
J&J: promising results for Imbruvica in leukemia	06-14	CF
Johnson & Johnson Reports Positive Long-Term Results for Talvey in Multiple Myeloma Study	06-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm